hotspot -WSS

hotspot

author：entertainment 2025-09-27 12:21:56 - browse：3

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： The cancer stories no one wants to hear

knowledge

WSS

Websites selling Wegovy, Zepbound ingredients targeted by FDA

'Null' research findings aren't empty of meaning. Let's publish them

Latigo launches with $135 million for Vertex

Flint parents haunted by uncertainty, fears of lead poisoning

The cancer stories no one wants to hear

Latigo launches with $135 million for Vertex

focus

hotspot

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

ACIP vaccine advisory panel sees its vacancies filled

The high cost of giving birth even with insurance

Artificial intelligence use in health care faces greater scrutiny in 2024

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why Eli Lilly’s earnings didn’t quite live up to the hype

DIEP, the 'gold standard' of breast reconstruction, is under threat

A controversial new treatment promises to make little people taller

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Chris Christie meets with Zelenskyy during Ukraine trip

focus

Here’s what’s in the FDA plan to include pregnant women in clinical trials

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Why Eli Lilly’s earnings didn’t quite live up to the hype

Too many hospitalized Covid

Ebola vaccine can save some who are already sick, per new study

H.R. 3 is the wrong path to lower drug costs

knowledge

hotspot

knowledge

explore